The long-term effects of probiotics in the therapy of ulcerative colitis: A clinical study (original) (raw)
Related papers
Clinical observation of probiotics combined with mesalazine in the treatment of ulcerative colitis
2019
To analyze the clinical efficacy of probiotics combined with mesalazine in the treatment of ulcerative colitis. 112 patients with ulcerative colitis admitted to the Department of Anorectal Surgery, Affiliated Hospital of Qingdao University from December 2016 to October 2018 were collected. The cases were randomly divided into control group (56 cases; mesalazine treatment) and study group (56 cases; Probiotics combined with mesalazine treatment). After 2 months, the inflammatory factor levels, treatment efficiency and adverse reactions were analyzed. The serum IL-6, TNF-α, and IFN-γ levels of the study group was superior to the control group (P<0.05). The total effective rate of treatment in the study group was 92.86%, which was significantly higher than that in the control group 76.79% (P<0.05). The incidence of adverse reactions in the study group was 7.14%, which was significantly lower than that of the control group 21.43% (P<0.05). Combined Probiotics and Mesalazine mai...
Probiotics for maintenance of remission in ulcerative colitis
Cochrane Database of Systematic Reviews, 2008
Analysis 2.3. Comparison 2 Probiotics versus 5-aminosalicylic acid (5-ASA) (mesalazine), Outcome 3 Serious adverse events...... Analysis 2.4. Comparison 2 Probiotics versus 5-aminosalicylic acid (5-ASA) (mesalazine), Outcome 4
Journal of Probiotics & Health
Background: Ulcerative colitis (UC) is one of the chronic, relapsing, inflammatory disorders of the gut and is characterized by inflammation limited in most cases to the colon. Since gut microbiota play a critical role in the development and perpetuation of intestinal inflammation, the addition of probiotics to this complex system may exert a positive influence on gut inflammatory reactions. Methods: A single center, open-label, intention-to-treat study involving patients with moderate-to-severe UC was performed to check whether a probiotic mixture containing Lactobacillus plantarum, Lactobacillus rhamnosus, and Bifidobacterium longum given together with a standard treatment could decrease clinical and histopathology indexes for UC evaluation. Results: The mixture given once a day for at least 2 months together with mesalazine and ciprofloxacin to patients in the acute phase of UC significantly reduced their Mayo Clinic Index values. Moreover, numbers of Lactobacilli isolated from patients feces were significantly increased, while those of Gram-negative rods decreased. The mixture given together with mesalazine to patients with UC in remission also caused a decrease of their clinical scores, but a more prominent and significant decrease of the histopathological index values in biopsy samples was observed. Conclusions: Supplementation of standard therapy with the probiotic mixture used in this study was efficacious in inducing and maintaining remission in UC, and this effect was related to modulation of dysbiosis in the gut microbiota.
Indian Journal of Medical Sciences, 2017
Background: The effects of probiotics on ulcerative colitis has still remained a contraversy. The aim of this study was to assess the effects of Lactobacillus casei strain ATCC PTA-3945 in treating ulcerative colitis. Materials and Methods: Thirty four patients with mild to moderately active ulcerative colitis randomly received a probiotic preparation of L. casei strain ATCC PTA-3945 (n = 17) or its placebo (n = 17) plus conventional medical therapy for their active disease. After a maximum of 2 months, remitted patients were again randomised to receive L. casei strain ATCC PTA-3945 or placebo, and also maintained on mesalazine or sulfasalazine tablets for a maximum of 6 months. Results: The numbers of patients achieving remission did not statistically differ between probiotic and placebo groups (82% vs. 76% at intention to treat analysis [P = 1.00], and 100% vs. 81.2% at per-protocol analysis [P = 0.23], respectively). The mean time to clinical remission were 25 days and 32 days in...
Journal of Crohn's and Colitis, 2008
Traditional medical treatments for ulcerative colitis (UC) are still compromised by its adverse effects and not potent enough to keep in remission for long-term periods. So, new therapies that are targeted at specific disease mechanisms have the potential to provide more effective and safe treatments for ulcerative colitis. Probiotics is recently introduced as a therapy for ulcerative colitis. In the present study, Lactobacillus acidophilus was selected as a probiotic therapy to investigate its effects in oxazolone-induced colitis model in rats that mimics the picture in human. The rats were grouped (8 rats each) as normal control group (Group I), Group II served as untreated oxazoloneinduced colitis, Group III oxazolone-induced colitis treated with probiotic L. acidophilus (1× 10 7 colony-forming units (CFU)/mL/day oral for 14 days), Group IV oxazolone-induced colitis treated with olsalazine (60 mg/kg/day oral for 14 days), Group V oxazolone-induced colitis treated with probiotic L. acidophilus and olsalazine in the same doses and duration. Disease activity index (DAI) was recorded, serum levels of C-reactive protein (CRP), tumor necrosis factor-α (TNF-α) and intrleukin-6 (IL-6) was assessed as inflammatory markers and the histopathological picture of the colon of each rat was studied. Disease activity index (DAI) showed significant positive correlation with the elevated serum levels of CRP (r =0.741, p b 0.05), TNF-α (r =0.802, p b 0.05) and IL-6 (r =0.801, p b 0.05). Treatment with either L. acidophilus (group III) or olsalazine (group IV) resulted in significant reduction in serum levels of CRP, TNF-α and IL-6, as well as disease activity index (DAI). Treatment with combination of L. acidophilus and olsalazine (group V) offered more significant reduction in serum levels of CRP, TNF-α, IL-6 and disease activity index (DAI) when compared to either group II (untreated group), group III (treated with L. acidophilus) or group IV (treated with olsalazine). So, it was concluded that L. acidophilus probiotic could be recommended as adjuvant therapy in combination with olsalazine to achieve more effective treatment for ulcerative colitis. For application in human, this needs to be verified in further clinical studies.
Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis
Alimentary Pharmacology & Therapeutics, 2006
SummaryBackgroundAminosalicylates are the mainstay of therapy to prevent relapse of quiescent ulcerative colitis. The rationale for using probiotics is based on the evidence implicating intestinal bacteria in the pathogenesis of this disorder.Aminosalicylates are the mainstay of therapy to prevent relapse of quiescent ulcerative colitis. The rationale for using probiotics is based on the evidence implicating intestinal bacteria in the pathogenesis of this disorder.AimTo evaluate the efficacy of Lactobacillus GG alone or in combination with mesalazine vs. mesalazine as maintenance treatment in ulcerative colitis.To evaluate the efficacy of Lactobacillus GG alone or in combination with mesalazine vs. mesalazine as maintenance treatment in ulcerative colitis.Patients and methods187 ulcerative colitis patients with quiescent disease were randomized to receive Lactobacillus GG 18 × 109 viable bacteria/day (65 patients), mesalazine 2400 mg/day (60 patients) or Lactobacillus GG + mesalazine (62 patients). Disease activity index, endoscopic and histological scores were determined at 0, 6 and 12 months and in case of relapse. The primary end point was to evaluate sustained remission.187 ulcerative colitis patients with quiescent disease were randomized to receive Lactobacillus GG 18 × 109 viable bacteria/day (65 patients), mesalazine 2400 mg/day (60 patients) or Lactobacillus GG + mesalazine (62 patients). Disease activity index, endoscopic and histological scores were determined at 0, 6 and 12 months and in case of relapse. The primary end point was to evaluate sustained remission.ResultsOverall analysis showed no difference in relapse rate at 6 (P = 0.44) and 12 months (P = 0.77) among the three treatment groups. However, the treatment with Lactobacillus GG seems to be more effective than standard treatment with mesalazine in prolonging the relapse-free time (P < 0.05).Overall analysis showed no difference in relapse rate at 6 (P = 0.44) and 12 months (P = 0.77) among the three treatment groups. However, the treatment with Lactobacillus GG seems to be more effective than standard treatment with mesalazine in prolonging the relapse-free time (P < 0.05).ConclusionsLactobacillus GG seems to be effective and safe for maintaining remission in patients with ulcerative colitis, and it could represent a good therapeutic option for preventing relapse in this group of patients.Lactobacillus GG seems to be effective and safe for maintaining remission in patients with ulcerative colitis, and it could represent a good therapeutic option for preventing relapse in this group of patients.
Functional Foods in Health and Disease, 2023
Background: In the recent decade, ulcerative colitis (UC) as a chronic inflammatory bowel disease has a growing incidence and prevalence in the world. Probiotics might be a promising approach to improve ulcerative colitis by favorably modifying the gut microbiota. Methods: A double-blind, randomized, placebo-controlled, parallel-group clinical trial was conducted on sixty patients with mild/moderate ulcerative colitis. Participants were administered either placebo (n = 30) or a multi-strain probiotic (n= 30) for 16 weeks. Clinical disease status, via Lichtiger and Mayo questionnaires, was assessed at baseline and after 8 and 16 weeks of intervention. Fecal calprotectin was measured before and after the study period. Within and between groups, comparisons were made using per-protocol (PP) and intention-to-treat (ITT) approaches, and a P-value≤0.05 was considered a statistically significant level. Results: Of the sixty patients who agreed to participate in the study, 18 dropped out during the study due to low compliance and gastrointestinal complications. The two groups were comparable in baseline variables (P>0.05). During the study, the within and between groups’ differences of calprotectin and Mayo scores were not statistically significant. Although the mean score of Lichtiger was significantly decreased in the probiotic group during the study period (P = 0.001), no statistically significant differences compared with the placebo group were seen. Conclusion: Our study elucidated that probiotic supplementation does not significantly improve UC patients, which may be due to the strain and dose administered. Future research should focus on the best effective strains and doses for ulcerative colitis. Keywords: probiotic, ulcerative colitis, IBD, clinical trial
Probiotic-Based Intervention in the Treatment of Ulcerative Colitis: Conventional and New Approaches
Biomedicines
Although there are number of available therapies for ulcerative colitis (UC), many patients are unresponsive to these treatments or experience secondary failure during treatment. Thus, the development of new therapies or alternative strategies with minimal side effects is inevitable. Strategies targeting dysbiosis of gut microbiota have been tested in the management of UC due to the unquestionable role of gut microbiota in the etiology of UC. Advanced molecular analyses of gut microbiomes revealed evident dysbiosis in UC patients, characterized by a reduced biodiversity of commensal microbiota. Administration of conventional probiotic strains is a commonly applied approach in the management of the disease to modify the gut microbiome, improve intestinal barrier integrity and function, and maintain a balanced immune response. However, conventional probiotics do not always provide the expected health benefits to a patient. Their benefits vary significantly, depending on the type and s...